Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
$8.82
-3.5%
$5.98
$3.75
$11.40
$141.30M2.4897,658 shs127,567 shs
Janone Inc. stock logo
ALTS
Janone
$8.96
+0.6%
$5.49
$1.29
$9.84
$156.40M2.14225,712 shs458,522 shs
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$5.00
-1.2%
$3.49
$1.97
$22.47
$149.65M1.2300,986 shs139,376 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$0.68
-2.1%
$0.68
$0.51
$1.53
$38.13M0.23181,754 shs68,596 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
-3.50%-16.56%+75.00%+44.59%+881,999,900.00%
Janone Inc. stock logo
ALTS
Janone
+0.56%+31.96%+41.77%+44.05%+895,999,900.00%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-1.19%-2.72%+48.81%+4.82%-77.18%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-2.05%+0.26%-5.96%-14.15%-53.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
1.5529 of 5 stars
3.50.00.00.02.70.80.0
Janone Inc. stock logo
ALTS
Janone
N/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
3.6918 of 5 stars
4.44.00.00.03.71.70.6
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
4.5112 of 5 stars
3.34.00.04.72.70.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$20.00126.76% Upside
Janone Inc. stock logo
ALTS
Janone
0.00
N/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83576.67% Upside
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.00633.14% Upside

Current Analyst Ratings Breakdown

Latest SPRO, ALTS, SLN, and ACOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
3/31/2025
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/25/2025
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy
3/18/2025
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
3/7/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
3/5/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.00
3/4/2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$6.00 ➝ $4.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
$2.93M48.25N/AN/A($1.08) per share-8.17
Janone Inc. stock logo
ALTS
Janone
$18.05M8.67N/AN/A($0.67) per share-13.37
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
$27.70M5.40N/AN/A$0.71 per share7.04
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$28.30M1.35$0.42 per share1.62$2.02 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
-$13.77M-$1.20N/AN/AN/AN/A-344.17%8/11/2025 (Estimated)
Janone Inc. stock logo
ALTS
Janone
-$7.81MN/A0.00N/AN/A-2,940.01%-39.81%N/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$22.81M-$1.289.74N/AN/A3.30%4.03%2.21%8/4/2025 (Estimated)

Latest SPRO, ALTS, SLN, and ACOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
5/8/2025Q1 2025
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
3/31/2025Q4 2024
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
-$0.48-$0.51-$0.03-$0.51N/AN/A
3/27/2025Q4 2024
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35-$0.38-$0.03-$0.38$12.40 million$15.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Janone Inc. stock logo
ALTS
Janone
$1.2213.62%N/AN/AN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$0.068.80%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
N/A
1.50
1.50
Janone Inc. stock logo
ALTS
Janone
1.96
0.75
0.75
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
N/A
9.31
9.31
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.68
2.68

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
N/A
Janone Inc. stock logo
ALTS
Janone
6.27%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
98.73%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
14.00%
Janone Inc. stock logo
ALTS
Janone
4.90%
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
2.95%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
4.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition, Inc. stock logo
ACOG
Alpha Cognition
N/A16.02 million10.97 millionN/A
Janone Inc. stock logo
ALTS
Janone
17017.46 million13.38 millionN/A
Silence Therapeutics plc stock logo
SLN
Silence Therapeutics
10029.93 millionN/ANot Optionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.05 millionOptionable

Recent News About These Companies

Spero Therapeutics Analyst Ratings
TD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)
Spero Therapeutics reports Q4 EPS (38c), consensus (31c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$8.82 -0.32 (-3.50%)
As of 05/27/2025 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Janone stock logo

Janone NASDAQ:ALTS

$8.96 +0.05 (+0.56%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.04 +0.08 (+0.89%)
As of 05/27/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.00 -0.06 (-1.19%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.02 +0.02 (+0.40%)
As of 05/27/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$0.68 -0.01 (-2.05%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.44%)
As of 05/27/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.